B6-hCCL1 Mouse
Product Name
B6-hCCL1 Mouse
Product ID
C001814
Strain Name
C57BL/6NCya-Ccl1tm1(hCCL1)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hCCL1 Mouse (Catalog C001814) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
CCL1
Gene Alias
P500, SISe, TCA3, I-309, SCYA1
NCBI ID
Chromosome
Chr 17 (Human)
MGI ID
Datasheet
Strain Description
The CCL1 (C-C motif chemokine ligand 1) gene, located on the q-arm of chromosome 17, encodes a small glycoprotein (approximately 15-16 kDa) belonging to the CC chemokine family. This protein, also known as I-309, is primarily expressed by activated T cells, monocytes/macrophages, and endothelial cells [1]. Its main function is as a chemoattractant, specifically drawing monocytes/macrophages, T lymphocytes (especially Th2-differentiated T cells and regulatory T cells), and some dendritic cells to sites of inflammation and immune responses. CCL1 exerts its effects by binding to the chemokine (C-C motif) receptor 8 (CCR8), which is found on various immune cells [2]. Beyond its role in immune cell trafficking, CCL1 has antimicrobial activity against bacteria like E. coli and S. aureus, and it can inhibit apoptosis in certain cell lines via the RAS/MAPK pathway [3]. CCL1 is implicated in various inflammatory and immune-related disorders, including asthma, atopic dermatitis, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), tuberculosis, and certain cancers like breast cancer, cervical cancer, and Kaposi Sarcoma, where its dysregulation can contribute to disease pathogenesis [3-4]. Cellular tissues where CCL1 expression is notable include the thymus, muscle, stomach, and various immune cells such as T cells, monocytes, B cells, and endothelial cells [4].
The B6-hCCL1 mouse is a humanized model, constructed by replacing the coding sequences of the endogenous mouse Ccl1 gene with the coding sequences of the human CCL1 gene. B6-hCCL1 mice can be used for research into the pathogenesis of various inflammatory and immune-related disorders, including asthma, atopic dermatitis, rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), tuberculosis, and certain cancers like breast cancer, cervical cancer, and Kaposi Sarcoma, as well as for the development of CCL1-targeted drugs.
Reference
Kishi H, Sato M, Shibata Y, Sato K, Inoue S, Abe S, Kimura T, Nishiwaki M, Yamauchi K, Nemoto T, Igarashi A, Tokairin Y, Nakajima O, Kubota I. Role of chemokine C-C motif ligand-1 in acute and chronic pulmonary inflammations. Springerplus. 2016 Aug 2;5(1):1241.
Sun D, Sun Y, Janezic E, Zhou T, Johnson M, Azumaya C, Noreng S, Chiu C, Seki A, Arenzana TL, Nicoludis JM, Shi Y, Wang B, Ho H, Joshi P, Tam C, Payandeh J, Comps-Agrar L, Wang J, Rutz S, Koerber JT, Masureel M. Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8. Nat Commun. 2023 Dec 1;14(1):7940.
Ciechanowska A, Mika J. CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings. Int J Mol Sci. 2024 Mar 28;25(7):3788.
Karin N. Chemokines and cancer: new immune checkpoints for cancer therapy. Curr Opin Immunol. 2018 Apr;51:140-145.
Strain Strategy
The sequences from the ATG start codon to the TAA stop codon of the endogenous mouse Ccl1 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human CCL1 gene.
Figure 1. Gene editing strategy of B6-hCCL1 Mice.
Application Area
CCL1-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of various inflammatory and immune-related disorders, including asthma, atopic dermatitis (AD), rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), tuberculosis;
Research on certain cancers like breast cancer, cervical cancer, and Kaposi Sarcoma.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
